Patients with a nonrejection-related diagnosis according to the 2019 Banff classification who were reclassified as MVI, ...

Lipocine (LPCN) announced that the FDA has recently informed sponsors of approved testosterone products about class-wide labeling changes. This ...

Risk factors are things that change our likelihood of developing a disease. Factors that may increase our risk of developing vascular dementia include age, genetics, lifestyle, and other health ...

High genetic susceptibility to type 2 diabetes is associated with higher atherosclerotic cardiovascular disease risk and ≤1 h/d of television viewing has substantially lower risk of atherosclerotic ...

A growing body of clinical evidence supports the use of Firefly's FDA-Cleared BNA(TM) platform to study ACP-01 as a treatment ...

AI-supported analyses could revolutionize neurological therapy for dementia. Canadian stem cell company Hemostemix Inc. (TSXV ...

Notably, the findings from this work may provide novel insight into the underlying mechanisms of PAD and, perhaps, have prevention or therapeutic ...

The following is a summary of "Engineering approach to study the effect of TEVAR on the cardiovascular system: A systematic ...

A free congenital heart disease screening camp for children between the ages of 0-18 years was held at District Hospital ...

Parkinson's Patients Have Improved Motor and Non-Motor Function After Treatment with Theralase(R) Cool Laser TherapyToronto, ...

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment ...

A new study has suggested that a simple eye test could be used to predict whether a person is at risk of having a stroke.